The expression levels of PD-1 on tumor infiltrating lymphocytes and tumor cell expression of PD-L1 and/or PD-L2 have been correlated with adverse clinical outcome in multiple studies of human DLBCL (44). Here, PDCD1LG2 is linked to neoplasm.